X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (117) 117
humans (116) 116
oncology (93) 93
female (72) 72
male (71) 71
aged (62) 62
middle aged (60) 60
article (52) 52
adult (45) 45
aged, 80 and over (36) 36
respiratory system (28) 28
treatment outcome (28) 28
chemotherapy (27) 27
abridged index medicus (26) 26
cancer (26) 26
clinical trials (26) 26
lung neoplasms - drug therapy (24) 24
carcinoma, non-small-cell lung - drug therapy (22) 22
lung neoplasms - pathology (22) 22
survival (22) 22
antineoplastic combined chemotherapy protocols - therapeutic use (19) 19
prognosis (19) 19
lung neoplasms - mortality (18) 18
research design (18) 18
carcinoma, non-small-cell lung - pathology (17) 17
neoplasms - drug therapy (17) 17
research (17) 17
disease-free survival (16) 16
lung cancer (15) 15
survival rate (15) 15
care and treatment (14) 14
dose-response relationship, drug (14) 14
medicine, research & experimental (14) 14
carcinoma, non-small-cell lung - mortality (13) 13
neoplasm staging (13) 13
pharmacology & pharmacy (13) 13
prospective studies (13) 13
toxicity (13) 13
disease progression (12) 12
hematology, oncology and palliative medicine (12) 12
maximum tolerated dose (12) 12
statistics & probability (12) 12
trial (12) 12
cell lung-cancer (11) 11
lung cancer, non-small cell (11) 11
pooled analysis (11) 11
risk factors (11) 11
therapy (11) 11
antineoplastic agents - therapeutic use (10) 10
cisplatin (10) 10
continual reassessment method (10) 10
follow-up studies (10) 10
lung neoplasms - radiotherapy (10) 10
models, statistical (10) 10
neoplasms - therapy (10) 10
predictive value of tests (10) 10
radiotherapy (10) 10
solid tumors (10) 10
survival analysis (10) 10
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
biomarker (9) 9
carcinoma, non-small-cell lung - genetics (9) 9
clinical trials as topic - methods (9) 9
genotype (9) 9
lung neoplasms - genetics (9) 9
neoplasms - pathology (9) 9
patient outcomes (9) 9
quality of life (9) 9
time factors (9) 9
antineoplastic agents - administration & dosage (8) 8
carcinoma (8) 8
computer simulation (8) 8
kaplan-meier estimate (8) 8
lung neoplasms - therapy (8) 8
mathematical & computational biology (8) 8
medical informatics (8) 8
non-small cell lung cancer (8) 8
pharmacokinetics (8) 8
progression-free survival (8) 8
young adult (8) 8
analysis (7) 7
antineoplastic agents - adverse effects (7) 7
leukemia (7) 7
medicine, general & internal (7) 7
paclitaxel (7) 7
proportional hazards models (7) 7
public, environmental & occupational health (7) 7
pulmonary and respiratory medicine (7) 7
reproducibility of results (7) 7
surgery (7) 7
tumor response (7) 7
adolescent (6) 6
bayes theorem (6) 6
biomarkers (6) 6
biomarkers, tumor - analysis (6) 6
breast-cancer (6) 6
carcinoma, non-small-cell lung - radiotherapy (6) 6
cardiac & cardiovascular systems (6) 6
cardiothoracic surgery (6) 6
clinical trials as topic (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Trials, ISSN 1740-7745, 12/2016, Volume 13, Issue 6, pp. 677 - 679
Journal Article
NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 04/2019, Volume 380, Issue 17, pp. 1680 - 1681
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2009, Volume 27, Issue 24, pp. 4027 - 4034
Purpose Biomarkers can add substantial value to current medical practice by providing an integrated approach to prediction using the genetic makeup of the... 
CELL LUNG-CANCER | POSITIVE BREAST-CANCER | ADJUVANT CHEMOTHERAPY | GROWTH-FACTOR RECEPTOR | SURVIVAL BENEFIT | ONCOLOGY | COLORECTAL-CANCER | PHASE-III | MINDACT TRIAL | GENE COPY NUMBER | GEFITINIB IRESSA | Clinical Trials as Topic | Retrospective Studies | Prospective Studies | Biomarkers, Tumor | Research Design | Humans | Index Medicus | To2 | Bios3 | Statistics in Oncology
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 5, pp. 454 - 464
Midostaurin, an oral multitargeted kinase inhibitor, is active in patients with a FLT3 mutation. Among patients with acute myeloid leukemia and this mutation,... 
TRIAL | INTERNAL TANDEM DUPLICATION | WILD-TYPE | MEDICINE, GENERAL & INTERNAL | FAVORABLE PROGNOSIS | ACUTE MYELOGENOUS LEUKEMIA | DISTINCT | TYROSINE KINASE INHIBITOR | SORAFENIB | PHASE-I | YOUNGER | Humans | Middle Aged | Kaplan-Meier Estimate | Staurosporine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Staurosporine - analogs & derivatives | Protein Kinase Inhibitors - adverse effects | Cytarabine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Mutation | Daunorubicin - administration & dosage | Leukemia, Myeloid, Acute - genetics | Staurosporine - administration & dosage | Chemotherapy | Care and treatment | Myelocytic leukemia | Nonlymphoid leukemia | Research | Drug therapy | Cancer | Tyrosine | Medical research | Inhibitor drugs | Myeloid leukemia | Leukemia | Clinical trials | Oncology | Transplantation | Kinases | Patients | Cancer therapies | Survival | Cytarabine | Daunorubicin | Medical prognosis | Point mutation | Death | Remission | Acute myeloid leukemia | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, pp. 3994 - 4003
The primary objective of phase I oncology trials is to find the MTD. The 3+3 design is easy to implement but performs poorly in finding the MTD. A newer... 
CONTINUAL REASSESSMENT METHOD | DOSE-ESCALATION | ONCOLOGY | CANCER | Medical research | Dosing | Toxicity | Clinical trials | Product design | Patients | Design | Upgrading | Design modifications | Keyboards | Overdose | Bayesian analysis | Cancer | Products liability | Index Medicus
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2018, Volume 379, Issue 26, pp. 2517 - 2528
Journal Article
Statistics in Medicine, ISSN 0277-6715, 01/2017, Volume 36, Issue 1, pp. 67 - 80
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2019, Volume 380, Issue 17, pp. 1679 - 1681
To the Editor: Woyach et al. (Dec. 27 issue) 1 report that in their trial involving patients who were 65 years of age or older with previously untreated... 
MEDICINE, GENERAL & INTERNAL | Pyrimidines | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Pyrazoles | Humans | Immunotherapy | Rituximab | Chronic lymphatic leukemia | Lymphatic leukemia | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 06/2018, Volume 13, Issue 6, pp. 745 - 747
Journal Article
Therapeutic Innovation & Regulatory Science, ISSN 2168-4790, 7/2014, Volume 48, Issue 4, pp. 453 - 462
Several recent publications have focused on statistical considerations that arise in multipopulation tailoring clinical trials that evaluate treatment effect... 
interaction condition | influence condition | familywise error rate | subgroup analysis | tailored therapeutics | POPULATION | BIOMARKER | TRASTUZUMAB | MEDICAL INFORMATICS | PRESPECIFIED SUBGROUP | HER2-POSITIVE BREAST-CANCER | ADAPTIVE SIGNATURE DESIGN | PHARMACOLOGY & PHARMACY
Journal Article
Journal of the Royal Statistical Society: Series C (Applied Statistics), ISSN 0035-9254, 02/2019, Volume 68, Issue 2, pp. 289 - 308
  The landscape of oncology drug development has recently changed with the emergence of molecularly targeted agents and immunotherapies. These new therapeutic... 
Bayesian adaptive design | Maximum tolerated dose | Dose finding | Exponential family distribution | CLINICAL-TRIALS | STATISTICS & PROBABILITY | REASSESSMENT METHOD | ESCALATION | Toxicity | Quality | Applications programs | Clinical trials | Scoring | Mathematical models | Pharmacology | Bayesian analysis | Chemical compounds | Drug dosages
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 05/2018, Volume 36, Issue 15, pp. e14524 - e14524
Conference Proceeding
Clinical Trials, ISSN 1740-7745, 10/2013, Volume 10, Issue 5, pp. 647 - 652
Journal Article